Novavax’s vaccine is a two-shot formula that can be stored at refrigerator temperatures.
The vaccine uses a “protein subunit” to fight the virus, directly putting a weakened version of the coronavirus spike protein into the immune system.
The Pfizer, Moderna, and Johnson & Johnson vaccines all provide genetic instructions for the body to build the virus’s spike protein, which helps the immune system learn to recognize and fight it.
Along with its promise to provide the U.S. with millions of doses, the company will also supply a total of 1.1 billion doses to developing countries.
Last month, vaccine alliance Gavi, part of the UN-backed COVAX initiative, announced that it signed an agreement to buy 350 million doses. The program has faced a shortage after its biggest supplier in India suspended exports until the end of 2021.
Novavax said it is applying for authorization in Britain, the European Union, India and South Korea.